Maintenance. We are currently updating the site. Please check back shortly

Thomson Reuters Foundation

Inform - Connect - Empower

EU medicines agency warns of stolen Roche cancer drug

Source: Reuters - Wed, 16 Apr 2014 12:16 GMT
Author: Reuters
hum-dis
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

(Adds Roche statement, details)

LONDON, April 16 (Reuters) - The European Medicines Agency warned on Wednesday that vials of Roche's breast cancer drug Herceptin, thought to have been stolen from hospitals in Italy, have been tampered with and reintroduced into the supply chain.

"Italian law enforcement authorities are currently investigating the theft and are looking at whether other medicines may also be affected," the agency said in a brief statement.

So far there have been no reports that any harm has come to patients who may have been given the stolen drug, which was sold under false credentials.

Healthcare professionals have been alerted to the falsified vials, which are labelled as Italian Herceptin 150 mg, the agency said.

In a separate statement Roche said that counterfeit Herceptin has been discovered in Britain, Finland and Germany.

A chemical analysis of one of the bogus vials found that the product did not contain the injectable cancer medicine's active ingredient, the company said. In other cases, there was evidence of tampering or dilution although the vials did contain Herceptin, it said.

"Such tampering could compromise the sterility or efficacy of the product putting the health and wellbeing of patients at risk," Roche said.

The Basel-based firm said it was recalling all vials suspected of being falsified as a precautionary measure.

Roche's drugs have been targeted by counterfeiters in the past. In 2012 bogus copies of its cancer drug Avastin entered the supply chain in the United States and Europe.

Herceptin is Roche's third-biggest seller with sales of 1.526 billion Swiss francs ($1.74 billion) in the first quarter of 2014. ($1=0.8793 Swiss Francs) (Reporting by Ben Hirschler and Caroline Copley; Editing by Kate Kelland, Greg Mahlich)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs